Drug intelligence / Profile preview

AV5126

Development stage: Preclinical
Lead developer: Viriom
Modality: Small Molecules

Overview

AV5126 is an experimental antiviral drug candidate from Viriom being developed in the company's respiratory virus portfolio, originally as an influenza medicine and later explored in 2020 for possible experimental use against COVID-19. Publicly available information identifies it only at the program level and does not clearly disclose its active ingredient, molecular target, precise mechanism of action, dosage form, or route of administration. Based on the available evidence, it is best characterized as a preclinical or early clinical-stage investigational antiviral asset with limited public disclosure.

Beyond the preview

Go deeper on AV5126.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AV5126.

Explore the full profile